NIS as a diagnostic marker for triple-negative breast cancer
Grigory A. Demyashkin,
Anastasia A. Guzik,
Dmitry V. Belokopytov,
Lyudmila N. Lyubchenko,
Alexander Yu. Tsibulevsky,
Diana M. Grigoryan EDN: NPRNEG
Abstract
Diagnosis of triple-negative breast cancer (TNBC) is challenging due to its low differentiation and the lack of reliable markers. Existing markers (Mammaglobin, GATA-3) possess insufficient sensitivity and/or specificity for the differential diagnosis of TNBC, especially in metastatic disease.
Objective - to compare the expression of NIS (sodium-iodide symporter), Mammaglobin, and GATA-3 in TNBC to evaluate the rationality and effectiveness of using NIS as a diagnostic marker.
Materials and methods. Retrospective study (n=161) of TNBC biopsy samples using immunohistochemical analysis (IHC) to assess the expression of NIS, Mammaglobin, and GATA-3.
Results. NIS showed the highest sensitivity (70.0%) compared to Mammaglobin (31.0%) and GATA-3 (63.7%). Combined use of NIS and GATA-3 achieved a sensitivity of 82.5%.
Conclusion. NIS is a promising marker for the diagnosis of TNBC, especially in combination with GATA-3.
About the Authors
Grigory A. Demyashkin
P.A. Herzen Moscow Oncology Research Institute - branch of the National Medical Research Radiological Center (P.A. Herzen MORI)
Russian Federation
Russian Federation
Anastasia A. Guzik
P.A. Herzen Moscow Oncology Research Institute - branch of the National Medical Research Radiological Center (P.A. Herzen MORI)
Russian Federation
Russian Federation
Dmitry V. Belokopytov
P.A. Herzen Moscow Oncology Research Institute - branch of the National Medical Research Radiological Center (P.A. Herzen MORI)
Russian Federation
Russian Federation
Lyudmila N. Lyubchenko
P.A. Herzen Moscow Oncology Research Institute - branch of the National Medical Research Radiological Center (P.A. Herzen MORI)
Russian Federation
Russian Federation
Alexander Yu. Tsibulevsky
Yu.E. Veltishchev Research and Clinical Institute for Pediatrics and Pediatric Surgery of the Pirogov Russian National Research Medical University (Yu.E. Veltishchev RCIPPS)
Russian Federation
Russian Federation
Diana M. Grigoryan
P.A. Herzen Moscow Oncology Research Institute - branch of the National Medical Research Radiological Center (P.A. Herzen MORI)
Russian Federation
Russian Federation
References
1. Boelaert K., Franklyn J.A. Sodium iodide symporter: a novel strategy to target breast, prostate, and other cancers? Lancet. 2003;361(9360):796-797. DOI: 10.1016/s0140-6736(03)12720-1.
2. Ravera S., Reyna-Neyra A., Ferrandino G., Amzel L.M., Carrasco N. The Sodium/Iodide Symporter (NIS): Molecular Physiology and Preclinical and Clinical Applications. Annu Rev Physiol. 2017;79:261-289. DOI: 10.1146/annurev-physiol-022516-034125.
3. De la Vieja A., Santisteban P. Role of iodide metabolism in physiology and cancer. Endocr Relat Cancer. 2018;25(4):R225-R245. DOI: 10.1530/ERC-17-0515.
4. Jhiang S.M., Sipos J.A. Na+/I- symporter expression, function, and regulation in non-thyroidal tissues and impact on thyroid cancer therapy. Endocr Relat Cancer. 2021;28(10):T167-T177. DOI: 10.1530/ERC-21-0035.
5. Cho J.Y., Léveillé R., Kao R., Rousset B., Parlow A.F., Burak W.E. Jr, Mazzaferri E.L., Jhiang S.M. Hormonal regulation of radioiodide uptake activity and Na+/I- symporter expression in mammary glands. J Clin Endocrinol Metab. 2000;85(8):2936-2943. DOI: 10.1210/jcem.85.8.6727.
6. Darabi N., Keshavarz M., Nabipour I., Assadi M. The sodium iodide symporter (NIS) as theranostic gene: Potential role in pre-clinical therapy of extra-thyroidal malignancies. Clinical and Translational Imaging. 2023;11(2):113-125. DOI: 10.1007/s40336-023-00540-0
7. Tazebay U.H., Wapnir I.L., Levy O., Dohan O., Zuckier L.S., Zhao Q.H., Deng H.F., Amenta P.S., et al. The mammary gland iodide transporter is expressed during lactation and in breast cancer. Nat Med. 2000;6(8):871-878. DOI: 10.1038/78630.
8. Berger F., Unterholzner S., Diebold J., Knesewitsch P., Hahn K., Spitzweg C. Mammary radioiodine accumulation due to functional sodium iodide symporter expression in a benign fibroadenoma. Biochem Biophys Res Commun. 2006;349(4):1258-1263. DOI: 10.1016/j.bbrc.2006.08.170.
9. Presta I., Arturi F., Ferretti E., Mattei T., Scarpelli D., Tosi E., Scipioni A., Celano M., et al. Recovery of NIS expression in thyroid cancer cells by overexpression of Pax8 gene. BMC Cancer. 2005;5:80. DOI: 10.1186/1471-2407-5-80.
10. Altorjay A., Dohán O., Szilágyi A., Paroder M., Wapnir I.L., Carrasco N. Expression of the Na+/I- symporter (NIS) is markedly decreased or absent in gastric cancer and intestinal metaplastic mucosa of Barrett esophagus. BMC Cancer. 2007;7:5. DOI: 10.1186/1471-2407-7-5.
11. Cimino-Mathews A. Novel uses of immunohistochemistry in breast pathology: interpretation and pitfalls. Mod Pathol. 2021;34(Suppl 1):62-77. DOI: 10.1038/s41379-020-00697-3.
12. Derakhshan F., Reis-Filho J.S. Pathogenesis of Triple-Negative Breast Cancer. Annu Rev Pathol. 2022;17:181-204. DOI: 10.1146/annurev-pathol-042420-093238.
13. Lin F., Liu H. Immunohistochemistry in undifferentiated neoplasm/tumor of uncertain origin. Arch Pathol Lab Med. 2014;138(12):1583-610. DOI: 10.5858/arpa.2014-0061-RA.
14. Gown A.M., Fulton R.S., Kandalaft P.L. Markers of metastatic carcinoma of breast origin. Histopathology. 2016;68(1):86-95. DOI: 10.1111/his.12877.
15. Krings G., Nystrom M., Mehdi I., Vohra P., Chen Y.Y. Diagnostic utility and sensitivities of GATA3 antibodies in triple-negative breast cancer. Hum Pathol. 2014;45(11):2225-2232. DOI: 10.1016/j.humpath.2014.06.022.
16. Gorbokon N., Timm P., Dum D., Menz A., Büscheck F., Völkel C., Hinsch A., Lennartz M., et al. Mammaglobin-A Expression Is Highly Specific for Tumors Derived from the Breast, the Female Genital Tract, and the Salivary Gland. Diagnostics (Basel). 2023;13(6):1202. DOI: 10.3390/diagnostics13061202.
17. Tuffaha M.S., Guski H., Kristiansen G. Immunohistochemistry in Tumor Diagnostics. Germany: Springer International Publishing, 2024.
18. Castro M.R., Bergert E.R., Beito T.G., McIver B., Goellner J.R., Morris J.C. Development of monoclonal antibodies against the human sodium iodide symporter: immunohistochemical characterization of this protein in thyroid cells. J Clin Endocrinol Metab. 1999;84(8):2957-2962. DOI: 10.1210/jcem.84.8.5871.
19. Sjödin A., Guo D., Hofer P.A., Henriksson R., Hedman H. Mammaglobin in normal human sweat glands and human sweat gland tumors. J Invest Dermatol. 2003;121(2):428-429. DOI: 10.1046/j.1523-1747.2003.12374.x.
20. Chang A., Amin A., Gabrielson E., Illei P., Roden R.B., Sharma R., Epstein J.I. Utility of GATA3 immunohistochemistry in differentiating urothelial carcinoma from prostate adenocarcinoma and squamous cell carcinomas of the uterine cervix, anus, and lung. Am J Surg Pathol. 2012;36(10):1472-1476. DOI: 10.1097/PAS.0b013e318260cde7.
21. Han J.H., Kang Y., Shin H.C., Kim H.S., Kang Y.M., Kim Y.B., Oh S.Y. Mammaglobin expression in lymph nodes is an important marker of metastatic breast carcinoma. Arch Pathol Lab Med. 2003;127(10): 1330-1334. DOI: 10.5858/2003-127-1330-MEILNI.
22. Deftereos G., Sanguino Ramirez A.M., Silverman J.F., Krishnamurti U. GATA3 immunohistochemistry expression in histologic subtypes of primary breast carcinoma and metastatic breast carcinoma cytology. Am J Surg Pathol. 2015;39(9):1282-1289. DOI: 10.1097/PAS.0000000000000505.
23. Kandalaft P.L., Simon R.A., Isacson C., Gown A.M.Comparative Sensitivities and Specificities of Antibodies to Breast Markers GCDFP-15, Mammaglobin A, and Different Clones of Antibodies to GATA-3: A Study of 338 Tumors Using Whole Sections. Appl Immunohistochem Mol Morphol. 2016;24(9):609-614. DOI: 10.1097/PAI.0000000000000237.
24. Renier C., Yao C., Goris M., Ghosh M., Katznelson L., Nowles K., Gambhir S.S., Wapnir I. Endogenous NIS expression in triple-negative breast cancers. Ann Surg Oncol. 2009;16(4):962-968. DOI: 10.1245/s10434-008-0280-9
25. Renier C., Vogel H., Offor O., Yao C., Wapnir I. Breast cancer brain metastases express the sodium iodide symporter. J Neurooncol. 2010;96(3):331-336. DOI: 10.1007/s11060-009-9971-8.
26. Romashchenko P.N., Maystrenko N.A., Simonova M.S., Krivolapov D.S. Prognostic potential of preoperative diagnostics of radioiodine-resistant well-differentiated thyroid cancer. Grekov's Bulletin of surgery. 2025;184(4):18-24 (in Russ.). DOI 10.24884/0042-4625-2025-184-4-18-24. EDN: XMJAWE.
27. Simonova M.S., Krivolapov D.S., Shinkarёv A.D. Molecular genetic testing in algorithm of treatment and diagnostic in patients with thyroid tumors.Russian Military Medical Academy reports. 2022;41(S2):385-389 (in Russ.). EDN: UDACIK.
28. Dzhikiya YE.L., Avilov O.N., Kiseleva Ya.Yu., Kulinich T.M., Bozhenko V.K. Sodium/iodide symporter (NIS): structure, function and role in in thyroid diseases. Vestnik of the Russian scientific center of roentgenoradiology. 2018;18(1):3 (in Russ.). EDN: XQWHNB.
Review
For citations:
Demyashkin G.A., Guzik A.A., Belokopytov D.V., Lyubchenko L.N., Tsibulevsky A.Yu., Grigoryan D.M. NIS as a diagnostic marker for triple-negative breast cancer. Humans and their health. 2025;28(4):75-83. (In Russ.) EDN: NPRNEG
Views:
90
JATS XML
Email this article 